Cure Pharmaceutical Secures Patent on High Loading of Active Ingredients in Oral Thin Film

GlobeNewswire•July 24, 2019 OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using…

CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

GlobeNewswire•July 16, 2019 OXNARD, Calif., July 16, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With…

Energy Fuels Commends President Trump on his Decision to Reinvigorate the Nuclear Fuel Supply Chain and Looks Forward to Working with the Trump Administration to Support the U.S. Uranium Mining Industry; First Land Cleanup Contract Signed

PR Newswire•July 15, 2019 LAKEWOOD, CO, July 15, 2019 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), the largest uranium producer in the U.S., is pleased to announce that our petition, filed jointly with Ur-Energy Inc. under Section 232 of the Trade Expansion Act of 1962, has been…

There Has Been No Announced Decision with Respect to the Uranium Section 232 Trade Action

PR NewswireJuly 12, 2019 DENVER, July 12, 2019 /PRNewswire/ — Ur-Energy Inc. (NYSE American: URG; TSX: URE) (“Ur-Energy”) and Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”) confirm that they are unaware of any decision by the White House with respect to the U.S. Department of Commerce (“DOC”) investigation into the effects of uranium…

CURE Pharmaceutical and Canopy Growth to Produce CBD Oral Thin Films

GlobeNewswire•June 19, 2019 OXNARD, Calif. , June 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. This CUREfilm…

Wealth and Wealth Copper Enter into Share Purchase Agreement to Acquire Escalones Copper-Gold Porphyry Project

GlobeNewswire•June 3, 2019 VANCOUVER, British Columbia, June 03, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN) announces that, further to its news releases dated December 4, 2018 and April 4, 2019, its wholly-owned subsidiary, Wealth Copper Ltd. (“Wealth Copper”) has entered into a…

CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

GlobeNewswire•May 22, 2019 OXNARD, Calif., May 22, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC). “Advances…

Cure Pharmaceutical Expands Leadership Team with Key New Hires

GlobeNewswire•May 20, 2019 OXNARD, Calif., May 20, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical(CURR), an innovative drug delivery and development company, today announced the addition of four key hires to their growing leadership team. Michael Redard will serve as CURE’s Chief Financial Officer. Josh Held becomes an independent new board member, Bhaumik Patel is CURE’s director…

CURE Pharmaceutical (OTCQB: CURR) Closes Acquisition Of Privately-Held Chemistry Holdings Inc.

GlobeNewswire•May 14, 2019 Acquired Technology Expands Core CUREfilmTM Platform and Strengthens Balance Sheet OXNARD, Calif., May 14, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical(CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has closed on the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is…